NASDAQ$TOI
Oncology Institute Inc/The · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported a strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
The Oncology Institute announced positive Q2 2023 results, demonstrating revenue growth and solid financial performance. Key strategic initiatives contributed to the company's success during the quarter.
- Revenue increased significantly compared to the previous quarter.
- Strategic initiatives drove growth and improved operational efficiency.
- The company maintained a strong financial position with healthy cash reserves.
- Positive outlook for the remainder of the year, with continued focus on growth strategies.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$80.2M
Revenue by segment
Oncology Institute · $82M total across 3 segments · Q3 2023
- Patient Services$53.6M+20.2%65.4%
- Dispensary$26.8M+42.2%32.7%
- Clinical Trials & Other$1.61M—2.0%
Forward guidance
The Oncology Institute anticipates continued growth and profitability in the coming quarters, driven by strategic expansion and improved service offerings.
Tailwinds
- Expected revenue growth in key geographic markets.
- Continued focus on improving patient outcomes and satisfaction.
- Strategic investments in new technologies and treatment modalities.
- Expansion of partnerships with leading healthcare providers.
- Strong pipeline of new service offerings and initiatives.
Headwinds
- Potential challenges related to regulatory changes and healthcare reform.
- Increased competition in the oncology services market.
- Uncertainties related to economic conditions and healthcare spending.
- Possible delays in the implementation of new strategic initiatives.
- Risk of unforeseen events impacting operations and financial performance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro